Randomized, placebo-controlled Phase 2a study of SPL026 met its primary endpoint demonstrating a clinically significant reduction in depressive ...

A phase 3 global trial is enrolling previously treated locally advanced/metastatic nonsquamous NSCLC to define DATROWAY efficacy and safety at scale. IDE034 is in open-label phase 1 ...